1. Home
  2. BAFN vs CRBP Comparison

BAFN vs CRBP Comparison

Compare BAFN & CRBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo BayFirst Financial Corp.

BAFN

BayFirst Financial Corp.

HOLD

Current Price

$8.10

Market Cap

40.6M

Sector

Finance

ML Signal

HOLD

Logo Corbus Pharmaceuticals Holdings Inc.

CRBP

Corbus Pharmaceuticals Holdings Inc.

HOLD

Current Price

$9.80

Market Cap

202.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BAFN
CRBP
Founded
1999
2009
Country
United States
United States
Employees
N/A
N/A
Industry
Savings Institutions
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
40.6M
202.6M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
BAFN
CRBP
Price
$8.10
$9.80
Analyst Decision
Strong Buy
Analyst Count
0
8
Target Price
N/A
$50.29
AVG Volume (30 Days)
6.4K
513.0K
Earning Date
01-29-2026
11-12-2025
Dividend Yield
1.94%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$58,931,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$100.00
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$6.40
$4.64
52 Week High
$19.75
$20.56

Technical Indicators

Market Signals
Indicator
BAFN
CRBP
Relative Strength Index (RSI) 44.54 34.73
Support Level $7.90 $9.44
Resistance Level $8.49 $11.64
Average True Range (ATR) 0.12 0.74
MACD 0.07 -0.02
Stochastic Oscillator 33.90 12.16

Price Performance

Historical Comparison
BAFN
CRBP

About BAFN BayFirst Financial Corp.

BayFirst Financial Corp is a bank holding company, it generates its revenue from interest on loans and the gain-on-sale income derived from the sale of loans into the secondary market. The company serves a broad spectrum of individuals, families, and small businesses, supported by national business lines in residential and SBA lending and technology platforms. The primary source of funding for its loans is deposits. BayFirst measures performance through net interest income after provision for loan losses, return on average assets, and return on average common equity, while maintaining appropriate regulatory leverage and risk-based capital ratios. The company has various segment such as Real Estate(Residential, Commercial, and Construction & Land), Commercial and Industrial, Consumer.

About CRBP Corbus Pharmaceuticals Holdings Inc.

Corbus Pharmaceuticals Holdings Inc is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.

Share on Social Networks: